Send to

Choose Destination
Gland Surg. 2014 Aug;3(3):203-6. doi: 10.3978/j.issn.2227-684X.2014.03.02.

HuR: a promising therapeutic target for angiogenesis.

Author information

1 Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China ; 2 Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an 710032, China.


Multiple angiogenic factors and inhibitors are becoming potential therapeutic targets for ischemia diseases and cancer. Posttranscriptional regulation through the untranslated region of mRNA is emerging as a critical regulating level in nearly all the biological processes. As a kind of RNA binding proteins, HuR plays important role in augmenting the hypoxic or inflammatory signal, stabilizing the resultant angiogenic factors and promoting the proliferation and migration of endothelial cells. These implicate HuR in the proangiogenic factors mediated angiogenesis in the hypoxia and inflammatory. We consider hypotheses that a more effective angiogenesis can be acquired through strengthened and prolonged effects of angiogenic factors, and that progresses in therapeutic angiogensis might also shed light on the implication of HuR in blocking tumor angiogensis. These considerations may help us to explain HuR as a promising therapeutic target for angiogenesis related disease. It may be a candidate in hypoxia therapy and cancer management.


HuR; angiogenesis; hypoxia; inflammatory

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center